AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05408871
Drug: adnectin 18F-BMS-986192 Head and Neck Cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Head and Neck Cancer: PET imaging will be performed after initial diagnosis and within 2 weeks of MRI or CT of the neck done as standard of care. MRI will include T1 weighted pre and post gadolinium spin echo, diffusion weighted imaging, and T2 weighted imaging. CT of the head and neck with contrast will be performed per standard clinical protocol. Patients will get one intravenous line and one radial artery line placed prior to imaging and up to 5.5mCi (204MBq) of \[18F\] PDL192 tracer will be administered intravenously, as a bolus, once the patient is positioned on the scanner. 42 PET data will be acquired at single bed position and in list mode for 120 min after the start of tracer administration. Samples will be drawn from radial artery line.
Trial: NCT05254548
Drug: Flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One daily dose of flurbiprofen 50 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).
Trial: NCT05026905
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: leucovorin 30mg BID day 1 to 7 on in a 2-week cycle
Trial: NCT05720494
Drug: JZP441
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral study drug administered for up to 4 weeks
Trial: NCT05720494
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo administered for up to 4 weeks
Trial: NCT04778059
Drug: USB002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USB002 is pharmaceutically formulated Angiotensin 1-7 \[A(1-7)\], a non-hypertensive derivative of Angiotensin-II (A-II), and is suspended in a vehicle as a sterile solution of USB002. Depending upon cohort assignment, subjects in the USB002 group will receive one of four doses of USB002 administered intravenously (IV).
Trial: NCT04778059
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo formulation will be the USB002 formulated solution without the addition of A(1-7). The placebo will be administered intravenously (IV).
Trial: NCT06622057
Drug: D07001-Softgel Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D07001-softgel capsule is an oral gemcitabine.
Trial: NCT06622057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo has the same excipient with D07001-softgel but without active pharmaceutical ingredients (APIs)
Trial: NCT04802343
Drug: BAY1817080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, tablet.
Trial: NCT04802343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, tablet.
Trial: NCT05711862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 0mg of placebo for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM.
Trial: NCT04863365
Drug: PHP-201 ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHP-201 0.5% ophthalmic solution, 3 drops daily, 28 days
Trial: NCT06328400
Drug: Deuremidevir Hydrobromide for Suspension
RxNorm normalized name: hydrobromic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, twice a day Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, 3 times a day Experimental: Deuremidevir Hydrobromide for Suspension 1200mg group, twice a day
Trial: NCT06328400
Drug: Deuremidevir Hydrobromide for Suspension Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, twice a day Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, 3 times a day Experimental: Deuremidevir Hydrobromide for Suspension 1200mg group, twice a day
Trial: NCT05218356
Drug: Covidir injections
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of the investigational product CODIVIR/Placebo at a dose of 20 mg twice a day subcutaneously at visits Day0-Day6 (7 days total)
Trial: NCT06623513
Drug: Indomethacin suppository
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin suppository 100 mg administered rectally 30 minutes before the ERCP procedure.
Trial: NCT05911828
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZY19489-FQ combination or placebo orally after a fasting period of at least 10 h.
Trial: NCT06061081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered.
Trial: NCT06457360
Drug: Ankaferd Blood Stopper
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of sterile gauze after extraction for hemostasis
Trial: NCT05186246
Drug: Combination cream
RxNorm normalized name: SUNSCREEN-35 PABA-FREE COMBINATION CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spent Grain Wax, Argan Oil, Shea Butter and Saccharide Isomerate Cream combination (10 gram), were applied on one side of the face twice daily by participants.
Trial: NCT05186246
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream that is identical looking were given to subjects to be applied on the other side of the face twice daily
Trial: NCT05730244
Drug: Cassia alata extract
RxNorm normalized name: Dioscorea alata whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml Cassia alata extract
Trial: NCT05730244
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml placebo solution
Trial: NCT05461261
Drug: Prednisolone Acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg Prednisolone Acetate will be given orally twice a day during treatment.
Trial: NCT05217238
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Advanced intravenous injection of remifentanil before the rocuronium injection
Trial: NCT05868356
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral adagrasib 200 mg twice daily (BID) for 8 days (Days 1 to 8). Predose PK blood samples for the measurement of adagrasib concentration will be collected on Days 2 to 7. Serial PK blood samples for adagrasib will be collected up to 12 hours postdose on Days 1 and 8.
Trial: NCT05868356
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral adagrasib 200 mg BID and gemfibrozil 600 mg BID for 10 days (Days 9 to 18), with no evening dose of adagrasib or gemfibrozil on Day 18. Predose PK blood samples for the measurement of adagrasib concentration will be collected on Days 9 to 17 before the morning dose of adagrasib. Predose PK blood samples for the measurement of gemfibrozil trough concentration will be collected on Days 15 to 18 before the morning dose of gemfibrozil. Serial PK blood samples for adagrasib will be collected up to 12 hours postdose on Day 18.
Trial: NCT06265272
Drug: Radiotracer Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will be requested to have a radiotracer injection of Ga-PSMA (Illucix, Telix Pharmaceuticals). An intravenous catheter will be placed in an arm or hand vein for injection of the Ga-PSMA;~* The catheter will be flushed post-injection with 0.9% saline solution~* The injected dose and the time of injection will be recorded.~* The subjects will be positioned on the scanner table; support devices under the back and/or legs will be used to enable the patient to comfortably maintain his/her position throughout the scan
Trial: NCT05482321
Drug: Definity Suspension for Injection
RxNorm normalized name: Definity Suspension for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * DEFINITY is administered as per manufactures instructions~* 1 vial of DEFINITY is allowed to warm to room temperature and activated by 45s shaking on a VIALMIX~* Withdraw the activated milky white suspension using the provided Dispensing Pin, PINSYNC or 18-20 gauge syringe needle, from the middle of the liquid in the inverted vial.~* Deliver a dose of 10 μl/kg of 'milky white suspension' IV as a bolus, delivered over 30seconds.~* Following imaging, provide a 10 mL flush of preservative-free saline~* Wait at least 30minutes until second dose (if provided).
Trial: NCT05254639
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg daily for 4 weeks + 10 mg daily for 12 weeks according to tolerance or efficacy
Trial: NCT04946929
Drug: Low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: half amount low molecular weight heparin
Trial: NCT06614998
Drug: Patients diagnosed with HLH-94 should be treated as soon as possible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For some highly suspicious patients, after diagnosis, according to the patient's etiology, the treatment plan should be determined as soon as possible, such as lymphoma-related patients treated with hormones combined with etoposide, which can greatly improve the prognosis of patients
Trial: NCT05093530
Drug: Neumifil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neumifil contains the active ingredient HEX17, a multivalent, glycan-targeting carbohydrate binding module (CBM). HEX17 CBM is suspended in an aqueous buffer solution containing 20 mM sodium phosphate, 50 mM NaCl (at pH 6.3), 5 % (v/v) glycerol and 0.5 % (v/v) polysorbate 80.
Trial: NCT05093530
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous buffer solution containing 20 mM sodium phosphate, 50 mM NaCl (at pH 6.3), 5 % (v/v) glycerol and 0.5 % (v/v) polysorbate 80.
Trial: NCT06666634
Drug: Sentinel node biopsy with either ICG-99mTc-nanoscan or 99mTc-nanoscan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sentinel node biopsy with either ICG-99mTc-nanoscan or 99mTc-nanoscan
Trial: NCT05573477
Drug: ATB-1011 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to ATB-1011
Trial: NCT05573477
Drug: ATB-1012 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to ATB-1012
Trial: NCT05573477
Drug: ATB-1013 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to ATB-1013
Trial: NCT04724629
Drug: Standard of care (SOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator (Corticoids and antiretrovirals)
Trial: NCT05287308
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxorubicin 50\~60mg/m2, i.v., d1, q3w or q2w.
Trial: NCT05287308
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide 600mg/m2, i.v., d1, q3w or q2w.
Trial: NCT04498325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplied by study
Trial: NCT05571644
Drug: mFOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycles before surgery
Trial: NCT06252051
Drug: Trivalent Influenza Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We divided the participants into three groups: one comprising healthy individuals, another consisting of those with type 2 diabetes mellitus (T2DM), and the last group comprising individuals with T2DM and chronic kidney disease (CKD). All participants will receive a trivalent influenza vaccine, and various parameters will be observed.
Trial: NCT05117554
Drug: casdatifan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT05117554
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT05440240
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depo-Medrol
Trial: NCT06537076
Drug: AR1005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR1005 inhibits sodium currents by selective binding to the inactive sodium channel, suppressing the release of the excitatory amino acid, glutamate.
Trial: NCT06537076
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for AR1005 to be administered BID for 20 weeks
Trial: NCT04105946
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: remifentanil administration intraoperatively in combination with other drugs used in TIVA
Trial: NCT05499260
Drug: CB03-154
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB03-154 tablet once daily.
Trial: NCT05499260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet once daily.
Trial: NCT06304805
Drug: cycle 1: treatment drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for cycle 1 treatment: participants are given the oral treatment specification (60 mg \*1 pill)
Trial: NCT06304805
Drug: cycle 1: reference drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for cycle 1 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)
Trial: NCT06304805
Drug: cycle 2: treatment drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for cycle 2 treatment: participants are given the oral treatment specification (60 mg \*1 pill)
Trial: NCT06304805
Drug: cycle 2: reference drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for cycle 2 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)
Trial: NCT06304805
Drug: cycle 3: treatment drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for cycle 3 treatment: participants are given the oral treatment specification (60 mg \*1 pill)
Trial: NCT06304805
Drug: cycle 3: reference drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for cycle 3 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)
Trial: NCT06200415
Drug: Glucosamine Sulfate
RxNorm normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine sulphate (GLcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of the chitosan with significant anti-inflammatory action.
Trial: NCT06621888
Drug: NTI164
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This intervention uses Full-Spectrum Medicinal Cannabis Plant Extract with a low THC concentration of 0.08% (NTI164), specifically formulated to treat pediatric acute-onset neuropsychiatric syndrome (PANS). The dosing regimen is carefully structured to increase from an initial 5 mg/kg per day up to a maximum of 20 mg/kg, tailored to individual tolerance levels. This gradual titration and the option to extend treatment up to 54 weeks distinguishes it from other interventions that may use different concentrations of THC or shorter treatment durations. The efficacy of NTI164 is rigorously assessed through psychological evaluations and biomarker analyses.
Trial: NCT00493662
Drug: Propylene Glycol 0.3%
RxNorm normalized name: PEG-400 0.4%/PROPYLENE GLYCOL 0.3% GEL,OPH
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06653608
Drug: Nano-reinforced calcium hydroxide medicament
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (Calcium hydroxide intracanal medicament reinforced with jasminum derived- titania nanoparticles)
Trial: NCT06653608
Drug: Calcium hydroxide without nanoparicles
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B ( Calcium hydroxide medicament without nanoparticles)
Trial: NCT05791448
Drug: RNA Transcription Modulator AU-409
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05863130
Drug: BI 764198 (C-14) (approach 1)
RxNorm normalized name: TRIOLEIN, 1-C-14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 764198 (C-14) (approach 1)
Trial: NCT06400459
Drug: IVW-1001 Ophthalmic Eyelid Wipe 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVW-1001 Ophthalmic Eyelid Wipe 0.1%
Trial: NCT06400459
Drug: IVW-1001 Ophthalmic Eyelid Wipe 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVW-1001 Ophthalmic Eyelid Wipe 0.2%
Trial: NCT06400459
Drug: IVW-1001 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVW-1001 Placebo
Trial: NCT06149065
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Masculinizing hormone therapy (testosterone) is used in female-to-male transgenders for medical reason.
Trial: NCT05670561
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PCIA formula#100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline. 30min before TACE treatment, the first dose of 2ml was slowly injected intravenously.No obvious adverse reactions were observed for 10min. The PCIA pump was commenced at the beginning of TACE. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h. The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.
Trial: NCT04641962
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT06126835
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women with UC exposed to conventional therapy (aminosalicylates, azathioprine, or mercaptopurine) during pregnancy
Trial: NCT06126835
Drug: Advanced therapy
RxNorm normalized name: Keri Advanced Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women with UC exposed to advanced therapy (infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, tofacitinib, cyclosporine, or tacrolimus) during pregnancy
Trial: NCT05619536
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile normal saline for injection
Trial: NCT04972968
Drug: Glucocorticoid
RxNorm normalized name: Glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT01000220
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06522945
Drug: TQD3524
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymyxin antibiotics
Trial: NCT05629494
Drug: Ibuprofen 400 mg, TID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Ibuprofen 400 mg 3 times per day for 10 days.
Trial: NCT06483243
Drug: Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At around 8 a.m., take Test drug or Reference drug 1,2,3(oral) with 200 mL of water at room temperature.
Trial: NCT06344533
Drug: JMKX003142 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JMKX003142 Injection will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.
Trial: NCT06344533
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.
Trial: NCT05518383
Drug: Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients with very limited disease (R1- stage I/II СR), the addition of rituximab might allow the omission of anthracyclines and vincristine without jeopardizing survival rates but reducing acute and long term toxicities. In this treatment arm, it is tested whether the event-free survival is similar to that of the historical control
Trial: NCT05518383
Drug: Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R2: Drug: Rituximab 2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second chemotherapy cycle
Trial: NCT05518383
Drug: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second
Trial: NCT05518383
Drug: Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab 4 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, Further
Trial: NCT05272696
Drug: Radical concurrent chemoradiotherapy
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with PR and maximum tumor diameter ≤ 3cm or CR evaluated by MDT after 2 courses induction therapy can receive Radical concurrent chemoradiotherapy. Evaluation was performed 3 months after CRT. After MDT discussion, patients with high-risk factors need maintenance treatment.
Trial: NCT05116306
Drug: Propylene glycol
RxNorm normalized name: Propylene Glycol
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lesion sterilization and tissue repair technique in non vital primary molars using double antibiotic paste mixed with Propylene glycol gel